Literature DB >> 18509378

Syncytia formation affects the yield and cytotoxicity of an adenovirus expressing a fusogenic glycoprotein at a late stage of replication.

S Guedan1, A Gros, M Cascallo, R Vile, E Mercade, R Alemany.   

Abstract

Fusogenic membrane glycoproteins (FMGs) may enhance the cytotoxicity of conditionally replicative adenoviruses. However, expression at early stages of infection impairs virus replication. We have inserted the hyperfusogenic form of the gibbon ape leukemia virus (GALV) envelope glycoprotein as a new splice unit of the major late promoter (MLP) to generate a replication-competent adenovirus expressing this protein. At high multiplicity of infection (MOI), this virus replicated efficiently forming clumps of fused cells and showing a faster release. In contrast, at low MOI, infected cells formed syncytia where only one nucleus contained virus DNA, decreasing total virus production but increasing cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18509378      PMCID: PMC3903089          DOI: 10.1038/gt.2008.94

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  23 in total

1.  Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth.

Authors:  A Bateman; F Bullough; S Murphy; L Emiliusen; D Lavillette; F L Cosset; R Cattaneo; S J Russell; R G Vile
Journal:  Cancer Res       Date:  2000-03-15       Impact factor: 12.701

2.  Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells.

Authors:  Andrew R Bateman; Kevin J Harrington; Tim Kottke; Atique Ahmed; Alan A Melcher; Michael J Gough; Emmanouela Linardakis; David Riddle; Allan Dietz; Christine M Lohse; Scott Strome; Tim Peterson; Robert Simari; Richard G Vile
Journal:  Cancer Res       Date:  2002-11-15       Impact factor: 12.701

3.  Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial.

Authors:  J Nemunaitis; I Ganly; F Khuri; J Arseneau; J Kuhn; T McCarty; S Landers; P Maples; L Romel; B Randlev; T Reid; S Kaye; D Kirn
Journal:  Cancer Res       Date:  2000-11-15       Impact factor: 12.701

Review 4.  Replicative adenoviruses for cancer therapy.

Authors:  R Alemany; C Balagué; D T Curiel
Journal:  Nat Biotechnol       Date:  2000-07       Impact factor: 54.908

5.  Human immunodeficiency virus type 1-mediated syncytium formation is compatible with adenovirus replication and facilitates efficient dispersion of viral gene products and de novo-synthesized virus particles.

Authors:  H Li; Y S Haviv; C A Derdeyn; J Lam; C Coolidge; E Hunter; D T Curiel; J L Blackwell
Journal:  Hum Gene Ther       Date:  2001-12-10       Impact factor: 5.695

6.  GCV modulates the antitumoural efficacy of a replicative adenovirus expressing the Tat8-TK as a late gene in a pancreatic tumour model.

Authors:  A Cascante; D Abate-Daga; L Garcia-Rodríguez; J R González; R Alemany; C Fillat
Journal:  Gene Ther       Date:  2007-08-23       Impact factor: 5.250

7.  Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect.

Authors:  Xinping Fu; Lihua Tao; Aiwu Jin; Richard Vile; Malcolm K Brenner; Xiaoliu Zhang
Journal:  Mol Ther       Date:  2003-06       Impact factor: 11.454

8.  Heat-directed tumor cell fusion.

Authors:  Anthony M Brade; Paul Szmitko; Duc Ngo; Fei-Fei Liu; Henry J Klamut
Journal:  Hum Gene Ther       Date:  2003-03-20       Impact factor: 5.695

9.  Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion.

Authors:  Emmanouela Linardakis; Andrew Bateman; Vy Phan; Atique Ahmed; Michael Gough; Kenneth Olivier; Rick Kennedy; Fiona Errington; Kevin J Harrington; Alan Melcher; Richard Vile
Journal:  Cancer Res       Date:  2002-10-01       Impact factor: 12.701

10.  Late expression of p53 from a replicating adenovirus improves tumor cell killing and is more tumor cell specific than expression of the adenoviral death protein.

Authors:  Harald Sauthoff; Teona Pipiya; Sheila Heitner; Shu Chen; Robert G Norman; William N Rom; John G Hay
Journal:  Hum Gene Ther       Date:  2002-10-10       Impact factor: 5.695

View more
  9 in total

1.  Verapamil enhances the antitumoral efficacy of oncolytic adenoviruses.

Authors:  Alena Gros; Cristina Puig; Sonia Guedan; Juan José Rojas; Ramon Alemany; Manel Cascallo
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

Review 2.  Oncolytic viruses: overcoming translational challenges.

Authors:  Jordi Martinez-Quintanilla; Ivan Seah; Melissa Chua; Khalid Shah
Journal:  J Clin Invest       Date:  2019-03-04       Impact factor: 14.808

3.  Minimal RB-responsive E1A promoter modification to attain potency, selectivity, and transgene-arming capacity in oncolytic adenoviruses.

Authors:  Juan J Rojas; Sonia Guedan; Peter F Searle; Jordi Martinez-Quintanilla; Raúl Gil-Hoyos; Francisca Alcayaga-Miranda; Manel Cascallo; Ramon Alemany
Journal:  Mol Ther       Date:  2010-08-31       Impact factor: 11.454

Review 4.  Use of cell fusion proteins to enhance adenoviral vector efficacy as an anti-cancer therapeutic.

Authors:  Joshua Del Papa; Ryan G Clarkin; Robin J Parks
Journal:  Cancer Gene Ther       Date:  2020-07-01       Impact factor: 5.987

5.  Active adenoviral vascular penetration by targeted formation of heterocellular endothelial-epithelial syncytia.

Authors:  Hannah H Chen; Ryan Cawood; Yasser El-Sherbini; Laura Purdie; Miriam Bazan-Peregrino; Leonard W Seymour; Robert C Carlisle
Journal:  Mol Ther       Date:  2010-09-28       Impact factor: 11.454

Review 6.  Adenoviral Vectors Armed with Cell Fusion-Inducing Proteins as Anti-Cancer Agents.

Authors:  Joshua Del Papa; Robin J Parks
Journal:  Viruses       Date:  2017-01-19       Impact factor: 5.048

Review 7.  Fusogenic Viruses in Oncolytic Immunotherapy.

Authors:  Teresa Krabbe; Jennifer Altomonte
Journal:  Cancers (Basel)       Date:  2018-06-26       Impact factor: 6.639

8.  An Oncolytic Adenovirus Vector Expressing p14 FAST Protein Induces Widespread Syncytium Formation and Reduces Tumor Growth Rate In Vivo.

Authors:  Josh Del Papa; Julia Petryk; John C Bell; Robin J Parks
Journal:  Mol Ther Oncolytics       Date:  2019-05-15       Impact factor: 7.200

Review 9.  Syncytia Formation in Oncolytic Virotherapy.

Authors:  Chase Burton; Eric Bartee
Journal:  Mol Ther Oncolytics       Date:  2019-10-01       Impact factor: 7.200

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.